Trade

with

Data not available

Open

-

Previous Close

-

Volume (Avg)

-

Day's Range

-

52Wk Range

-

Market Cap.

-

P/E Ratio (EPS

-

Dividend Rate ( Yield )

-

Beta

1.23

Shares Outstanding

236.16M

P/E Ratio (EPS)

- (10.56)

AdChoices
Financials
  • Income Statement
  • Balance Sheet
  • Cash Flow
Operating Income
2.52B
Operating Margin
36.29
Total Equity
-
Retained Earnings
-
Free Cashflow
-
Price/Cashflow
28.09
Ownership

Institutional Ownership

94.78%

Top 10 Institutions

45.11%

Mutual Fund Ownership

58.50%

Float

89.74%

5% / Insider Ownership

0.77%

Corporate insiders or major stockholders reporting trading activity in the stock.

Top Mutual Fund Owners

Top Institutional Owners

Mutual Fund Name

Institution Name

  • Mutual Fund Name

  • Shares Held

  • % Change

  • % Outstanding

  • Vanguard PrimeCap Fund

  •  

    9,973,695

  • -0.99

  • 4.20

  • Fidelity® Contrafund® Fund

  •  

    8,238,199

  • 2.04

  • 3.49

  • Vanguard Total Stock Mkt Idx

  •  

    3,866,612

  • 0.44

  • 1.64

  • VA CollegeAmerica Growth Fund of America

  •  

    3,452,200

  • -11.37

  • 1.46

  • ClearBridge Aggressive Growth Fund

  •  

    3,292,304

  • 0.00

  • 1.39

  • Vanguard Capital Opportunity Fund

  •  

    2,765,438

  • -0.72

  • 1.17

  • T. Rowe Price Growth Stock Fund

  •  

    2,720,000

  • -1.28

  • 1.15

  • Vanguard Five Hundred Index Fund

  •  

    2,451,596

  • -0.21

  • 1.04

  • Vanguard Institutional Index Fund

  •  

    2,392,392

  • -1.50

  • 1.01

  • SPDR® S&P 500 ETF

  •  

    2,324,135

  • 1.59

  • 0.92

  • Institution Name

  • Shares Held

  • % Change

  • % Outstanding

  • Fidelity Management and Research Company

  •  

    21,066,939

  • -3.71%

  • 8.88

  • PRIMECAP Management Company

  •  

    17,258,311

  • -1.39%

  • 7.28

  • T. Rowe Price Associates, Inc.

  •  

    12,194,641

  • +0.14%

  • 5.14

  • Vanguard Group, Inc.

  •  

    12,086,297

  • +1.57%

  • 5.10

  • State Street Corp

  •  

    9,638,717

  • +0.96%

  • 4.06

  • Capital Research Global Investors

  •  

    8,198,550

  • -4.04%

  • 3.46

  • ClearBridge Advisors, LLC

  •  

    7,893,874

  • +2.47%

  • 3.33

  • BlackRock Fund Advisors

  •  

    7,271,790

  • +2.08%

  • 3.07

  • Jennison Associates LLC

  •  

    6,280,884

  • -0.89%

  • 2.65

  • J.P. Morgan Investment Management Inc.

  •  

    5,081,303

  • +14.70%

  • 2.14

Company Profile

Sector

Healthcare

Industry

Biotechnology

Type

Aggressive Growth

Style

Large Growth

Biogen Idec Inc was formed as a California corporation in 1985 and became a Delaware corporation in 1985. The Company is a biotechnology company focused. It discovers, develops, manufactures and markets therapies for the treatment of...more multiple sclerosis (MS) and other autoimmune disorders, neurodegenerative diseases and hemophilia. It also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions. The Company's marketed products include MA Products, AVONEX; TYSABRI; RITUXAN; FAMPYRA; FUMADERM. The Company develop, manufacture and market a number of products designed to treat patients with MS. MS is a progressive neurological disease in which the body loses the ability to transmit messages along nerve...more cells, to a loss of muscle control, paralysis and, in some cases, death. AVONEX is one of the prescribed treatments for relapsing forms of MS. TYSABRI has advanced the treatment of relapsing MS with its established efficacy. TYSABRI is a monoclonal antibody approved in numerous countries as a monotherapy treatment for relapsing MS and also approved in the U.S. to treat Crohn's disease, an inflammatory disease of the intestines. RITUXAN is a prescribed monoclonal antibody therapeutic used to treat non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia and two forms of ANCA-associated vasculitis. FAMPYRA is the first treatment that addresses the unmet medical need of walking improvement in adult patients with MS who have walking disability. FAMPYRA is a prolonged-release tablet formulation of the drug fampridine. The Company is facing competition from other biotechnology firms and large pharmaceutical companies. The Company is subject to various federal and state laws pertaining to health care fraud and abuse, including anti-kickback laws and false claims laws.lessless

Key People

Dr. George A. Scangos,PhD

CEO/Director

Dr. Stelios Papadopoulos,PhD

Director/Chairman of the Board

Mr. Paul J. Clancy

CFO/Executive VP, Divisional

Dr. Douglas E. Williams,PhD

Executive VP, Divisional

Steven H. Holtzman

Executive VP, Divisional

  • Biogen Idec Inc

  • 225 Binney Street

  • Cambridge, MA 02142

  • USA.Map

  • Phone: +1 617 679-2000

  • Fax: -

  • biogenidec.com

Incorporated

1985

Employees

6,850

Send Feedback

We appreciate your input!

  • I'm having trouble signing into my Microsoft account

  • I’m having problems with the services stripe (Mail, Facebook, etc.)

  • There is an issue with my weather information

  • I see an error in the content

  • Other

Please give an overall site rating: